A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Phase 1 Active not recruiting 86 enrolled Erasca, Inc.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors

Timeline

Start: 2023-08-17
Primary completion: 2025-07-01
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naporafenib	Small molecule	200 mg	—
Subject	Trametinib	Small molecule	1 mg	—

Indications

No indication recorded.